地舒单抗治疗糖皮质激素骨质疏松研究进展

Research progress in the treatment of glucocorticoid-induced osteoporosis with denosumab

糖皮质激素性骨质疏松症(GIOP)是激素最常见的不良反应之一,严重者可致骨质疏松性骨折,其治疗及预防是目前研究的重点。地舒单抗是核因子κB受体活化因子配体(RANKL)单抗类药物,在我国适应症包括实体肿瘤骨转移、多发骨髓瘤、骨巨细胞瘤及骨折高风险的绝经后妇女的骨质疏松症,目前尚未被批准用于治疗糖皮质激素性骨质疏松症。本文总结了糖皮质激素性骨质疏松症的发病机制,并更新了地舒单抗治疗糖皮质激素性骨质疏松症相关临床试验结果,为临床糖皮质激素性骨质疏松症的治疗提供参考。

Glucocorticoid-induced osteoporosis(GIOP)is one of the most common adverse reactions of glucocorticoids,severe cases can cause osteoporotic fracture.Its treatmentand prevention are the focus of current research.Denosumab is a nuclear factorκB receptor activator ligand(RANKL)monoclonal antibody.In China,it was approved to treat bone metastasis from solid tumors,multiple myeloma,giant cell tumor of bone and postmenopausal women with high risk of fracture,but it has not been approved to treat glucocorticoid-induced osteoporosis.This article reviews the pathogenesis of glucocorticoid-induced osteoporosis,and updates the result of clinical trials related to denosumab in the treatment of glucocorticoid-induced osteoporosis,so as to provide reference for the treatment of glucocorticoid-induced osteoporosis.